• Publications
  • Influence

Claim Your Author Page
Ensure your research is discoverable on Semantic Scholar. Claiming your author page allows you to personalize the information displayed and manage your publications. Semantic Scholar automatically creates author pages based on data aggregated from public sources and our publisher partners.
  • Atsushi Nishikawa, Takehiro Ishida, Masanori Taketsuna, Fumito Yoshiki, Hiroyuki Enomoto
  • Medicine
  • Clinical interventions in aging
  • 2016 (First Publication: 6 July 2016)
  • This postmarketing surveillance study assessed the safety and effectiveness of teriparatide in patients with osteoporosis at high risk of fracture in Japan. The patients received teriparatide 20 μgExpand
  • Hiroyoshi Yamazaki, Noriko Kobayashi, Masanori Taketsuna, Koyuki Tajima, Nahoko Suzuki, Masahiro Murakami
  • Medicine
  • Current medical research and opinion
  • 2017 (First Publication: 20 July 2017)
  • Abstract Objective: To evaluate the long-term safety and effectiveness of tadalafil in pediatric patients with pulmonary arterial hypertension (PAH) in real-world clinical practice. Methods: This isExpand
  • Yasuhiro Takeuchi, Etsuro Hamaya, Masanori Taketsuna, Hideaki Sowa
  • Medicine
  • Menopause
  • 2015 (First Publication: 1 October 2015)
  • Objective:Long-term safety of medication is a concern for older persons because they may have several comorbidities that can influence drug metabolism, efficacy, and safety. In Japan, raloxifene isExpand
  • Atsushi Nishikawa, Fumito Yoshiki, Masanori Taketsuna, Kenta Kajimoto, Hiroyuki Enomoto
  • Medicine
  • Clinical interventions in aging
  • 2016 (First Publication: 15 November 2016)
  • Teriparatide (recombinant 1–34 N-terminal sequence of human parathyroid hormone) for the treatment of osteoporosis should be prescribed with caution in patients with severe stages of chronic kidneyExpand
  • Fumito Yoshiki, Atsushi Nishikawa, Masanori Taketsuna, Kenta Kajimoto, Hiroyuki Enomoto
  • Medicine
  • Journal of orthopaedic science : official journal…
  • 2017 (First Publication: 1 March 2017)
  • BACKGROUND Teriparatide is the first anabolic agent shown to reduce the risk of fractures in patients with osteoporosis. In Japan, teriparatide is prescribed to treat patients at high risk ofExpand
  • Takanori Yamamoto, Masanori Taketsuna, Xiaoyan Guo, Masayo Sato, Hideaki Sowa
  • Medicine
  • Journal of Bone and Mineral Metabolism
  • 2013 (First Publication: 1 November 2014)
  • This postmarketing surveillance study assessed the safety and effectiveness of daily teriparatide treatment in patients with osteoporosis in a Japanese clinical setting. In this prospective,Expand